1. <cite id="5wyk8"><noscript id="5wyk8"></noscript></cite>
      <tt id="5wyk8"><noscript id="5wyk8"></noscript></tt>
      <tt id="5wyk8"><noscript id="5wyk8"></noscript></tt>

        <rt id="5wyk8"><meter id="5wyk8"></meter></rt>
          <source id="5wyk8"><menuitem id="5wyk8"></menuitem></source>
          <rt id="5wyk8"><optgroup id="5wyk8"></optgroup></rt>
        1. <ruby id="5wyk8"></ruby>

          Pipeline

          Gilead’s research and development program identifies and evaluates investigational compounds that show potential to advance the treatment of life-threatening diseases in areas of unmet medical need.

          Pipeline

          HIV / AIDS

          Gilead is committed to pursuing innovation in HIV across the spectrum of care. We are working to address remaining needs in both prevention and treatment. And, we are focused on discovery research that could potentially, one day, lead to a cure.

          The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

          • Emtricitabine and tenofovir alafenamide

            Potential Indication: PrEP

            Phase 1
            Phase 2
            Phase 3
          • GS-9131 (NRTI)

            Potential Indication: HIV/AIDS

            Phase 1
            Phase 2
            Phase 3
          • GS-6207 (Capsid Inhibitor)

            Potential Indication: HIV/AIDS

            Phase 1
            Phase 2
            Phase 3
          • Vesatolimod (TLR-7 agonist)

            Potential Indication: HIV/AIDS

            Phase 1
            Phase 2
            Phase 3
          • GS-9722 (bNab)

            Potential Indication: HIV/AIDS

            Phase 1
            Phase 2
            Phase 3

          Liver Diseases

          Gilead’s liver disease research focuses on investigating medicines for patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH) and for potentially curing patients chronically infected with the hepatitis B virus (HBV).

          The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

          • Selonsertib (ASK-1 inhibitor)

            Potential Indication: DKD

            Phase 1
            Phase 2
            Phase 3
          • Cilofexor (FXR agonist)

            Potential Indication: NASH

            Phase 1
            Phase 2
            Phase 3
          • Cilofexor (FXR agonist)

            Potential Indication: Primary Biliary Cirrhosis

            Phase 1
            Phase 2
            Phase 3
          • Cilofexor (FXR agonist)

            Potential Indication: Primary Sclerosing Cholangitis

            Phase 1
            Phase 2
            Phase 3
          • Firsocostat (ACC Inhibitor)

            Potential Indication: NASH

            Phase 1
            Phase 2
            Phase 3
          • GS-9688 (TLR-8 agonist)

            Potential Indication: HBV

            Phase 1
            Phase 2
            Phase 3
          • GS-4224 (PD-L1)

            Potential Indication: HBV

            Phase 1
            Phase 2
            Phase 3

          Hematology / Oncology

          Gilead is advancing a pipeline of cancer therapies in the areas of cell therapy, immuno-oncology and targeted therapies. Following the 2017 acquisition of Kite Pharma, Inc., our leading cell therapy pipeline now includes investigational cell therapies and next-generation technologies for a range of hematologic malignancies and solid tumors.

          The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

          • Axicabtagene ciloleucel

            Trial: ZUMA-5 Potential Indication: Indolent NHL

            Phase 1
            Phase 2
            Phase 3
          • Axicabtagene ciloleucel

            Trial: ZUMA-6 Potential Indication: DLBCL (PD-L1 mAb)

            Phase 1
            Phase 2
            Phase 3
          • Axicabtagene ciloleucel

            Trial: ZUMA-7 Potential Indication: 2nd line DLBCL

            Phase 1
            Phase 2
            Phase 3
          • Axicabtagene ciloeucel

            Trial: ZUMA-11 Potential Indication: DLBCL (41BB)

            Phase 1
            Phase 2
            Phase 3
          • Axicabtagene ciloeucel

            Trial: ZUMA-12 Potential Indication: 1st line DLBCL

            Phase 1
            Phase 2
            Phase 3
          • KTE-X19

            Trial: ZUMA-2 Potential Indication: MCL

            Phase 1
            Phase 2
            Phase 3
          • KTE-X19

            Trial: ZUMA-3 Potential Indication: Adult ALL

            Phase 1
            Phase 2
            Phase 3
          • KTE-X19

            Trial: ZUMA-4 Potential Indication: Pediatric ALL

            Phase 1
            Phase 2
            Phase 3
          • KTE-X19

            Trial: ZUMA-8 Potential Indication: CLL

            Phase 1
            Phase 2
            Phase 3
          • KITE-718 (MAGE A3/A6)

            Potential Indication: Solid Tumor

            Phase 1
            Phase 2
            Phase 3
          • KITE-439 (HPV E7)

            Potential Indication: Solid Tumor

            Phase 1
            Phase 2
            Phase 3
          • Tirabrutinib (BTK inhibitor)

            Potential Indication: B-cell malignancies

            Phase 1
            Phase 2
            Phase 3

          Inflammation / Respiratory

          Gilead is advancing a pipeline of novel investigational agents for inflammatory diseases, addressing multiple targets with potential application across a broad range of disorders.

          The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

          • Filgotinib (JAK1 inhibitor)

            Potential Indication: Rheumatoid Arthritis

            Phase 1
            Phase 2
            Phase 3
          • Filgotinib (JAK1 inhibitor)

            Potential Indication: Crohn's Disease

            Phase 1
            Phase 2
            Phase 3
          • Filgotinib (JAK1 inhibitor)

            Potential Indication: Ulcerative Colitis

            Phase 1
            Phase 2
            Phase 3
          • Filgotinib (JAK1 inhibitor)

            Potential Indication: Inflammatory Diseases

            Phase 1
            Phase 2
            Phase 3
          • GS-9876 (Syk inhibitor)

            Potential Indication: Sjogren’s Syndrome

            Phase 1
            Phase 2
            Phase 3
          • GS-9876 (Syk inhibitor)

            Potential Indication: Lupus

            Phase 1
            Phase 2
            Phase 3
          • GS-4875 (TPL2 inhibitor)

            Potential Indication: Inflammatory Bowel Disease

            Phase 1
            Phase 2
            Phase 3

          Other

          Gilead is collaborating with U.S. Department of Defense, Centers for Disease Control and Prevention, and National Institutes of Health as well as multiple academic institutions to discover and develop novel antivirals for highly pathogenic infections and neglected/emerging viral diseases, including Ebola.

          The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

          • Remdesivir (GS-5734, Nuc inhibitor)

            Potential Indication: Ebola Virus Infection

            Phase 1
            Phase 2
            Phase 3
          天天看片